I am a long-term cancer survivor and cancer coach who works with head and neck cancer patients, survivors and caregivers to research and identify both conventional (FDA approved) and evidence-based non-conventional therapies to enable these cancer patients to go beyond those therapies offered by their oncologist.
It no longer is enough to say “I have head and neck cancer.” Nor is it enough to say “I have stage 2 head and neck cancer.” As the article linked below explains,
“The expanding knowledge of the underlying molecular abnormalities in this once very poorly understood cancer should allow for increasingly rational clinical trial design and improved patient outcomes…”
The good news is that oncology understand HNSCC cancer much better today that ever before. The bad news is that head and neck cancer is still complicated and often difficult to treat.
The takeaway for head and neck cancer patients is that getting a specific diagnosis of your cancer is the foundation of your prognosis and therapy plan.
Have you been diagnosed with head and neck cancer? Do you know the molecular make-up of your cancer? Would you like some help in trying to figure out this complicated diagnosis? Please scroll down the page, post a question or comment and I will reply to you ASAP.
Hang in there and thanks,
“The past decade has seen an unprecedented increase in our understanding of the biology and etiology of head and neck squamous cell carcinomas (HNSCC). Genome-wide sequencing projects have identified a number of recurrently mutated genes, including unexpected alterations in the NOTCH pathway and chromatin related genes…
Gene-expression profiling has identified 4 distinct genetic subtypes which show some parallels to lung squamous cell carcinoma biology…
The identification of the human papilloma virus as one causative agent in a subset of oropharyn cancers and their association with a favorable prognosis has opened up avenues for new therapeutic strategies...
Furthermore, oncogenic pathways can be activated by non-genetic mechanisms, which would not have been detected by genomic efforts. Now that a genetic blueprint for HNSCC has been completed, the challenge moving forward will be to identify ways to use this information to develop improved diagnostic and therapeutic modalities…”